• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

平行合成策略在发现作为高效且选择性的 NaV1.7 抑制剂的联芳基酰基磺酰胺中的应用。

Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors.

作者信息

DiMauro Erin F, Altmann Stephen, Berry Loren M, Bregman Howard, Chakka Nagasree, Chu-Moyer Margaret, Bojic Elma Feric, Foti Robert S, Fremeau Robert, Gao Hua, Gunaydin Hakan, Guzman-Perez Angel, Hall Brian E, Huang Hongbing, Jarosh Michael, Kornecook Thomas, Lee Josie, Ligutti Joseph, Liu Dong, Moyer Bryan D, Ortuno Daniel, Rose Paul E, Schenkel Laurie B, Taborn Kristin, Wang Jean, Wang Yan, Yu Violeta, Weiss Matthew M

机构信息

Department of Neuroscience, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States.

出版信息

J Med Chem. 2016 Sep 8;59(17):7818-39. doi: 10.1021/acs.jmedchem.6b00425. Epub 2016 Aug 29.

DOI:10.1021/acs.jmedchem.6b00425
PMID:27441383
Abstract

The majority of potent and selective hNaV1.7 inhibitors possess common pharmacophoric features that include a heteroaryl sulfonamide headgroup and a lipophilic aromatic tail group. Recently, reports of similar aromatic tail groups in combination with an acyl sulfonamide headgroup have emerged, with the acyl sulfonamide bestowing levels of selectivity over hNaV1.5 comparable to the heteroaryl sulfonamide. Beginning with commercially available carboxylic acids that met selected pharmacophoric requirements in the lipophilic tail, a parallel synthetic approach was applied to rapidly generate the derived acyl sulfonamides. A biaryl acyl sulfonamide hit from this library was elaborated, optimizing for potency and selectivity with attention to physicochemical properties. The resulting novel leads are potent, ligand and lipophilic efficient, and selective over hNaV1.5. Representative lead 36 demonstrates selectivity over other human NaV isoforms and good pharmacokinetics in rodents. The biaryl acyl sulfonamides reported herein may also offer ADME advantages over known heteroaryl sulfonamide inhibitors.

摘要

大多数强效且具有选择性的hNaV1.7抑制剂具有共同的药效基团特征,包括一个杂芳基磺酰胺头部基团和一个亲脂性芳族尾部基团。最近,出现了类似芳族尾部基团与酰基磺酰胺头部基团结合的报道,其中酰基磺酰胺赋予的对hNaV1.5的选择性水平与杂芳基磺酰胺相当。从满足亲脂性尾部选定药效基团要求的市售羧酸开始,采用平行合成方法快速生成衍生的酰基磺酰胺。对该文库中得到的一个联芳基酰基磺酰胺命中物进行了优化,在关注物理化学性质的同时优化其效力和选择性。所得的新型先导化合物效力强、配体及亲脂性高效,且对hNaV1.5具有选择性。代表性先导化合物36对其他人类NaV亚型具有选择性,并且在啮齿动物中具有良好的药代动力学性质。本文报道的联芳基酰基磺酰胺与已知的杂芳基磺酰胺抑制剂相比,可能还具有药物吸收、分布、代谢和排泄方面的优势。

相似文献

1
Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors.平行合成策略在发现作为高效且选择性的 NaV1.7 抑制剂的联芳基酰基磺酰胺中的应用。
J Med Chem. 2016 Sep 8;59(17):7818-39. doi: 10.1021/acs.jmedchem.6b00425. Epub 2016 Aug 29.
2
Sulfonamides as Selective Na1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.作为选择性Na1.7抑制剂的磺胺类药物:优化效力、药代动力学和代谢特性以获得具有强大体内活性的阻转异构喹啉酮(AM-0466)。
J Med Chem. 2017 Jul 27;60(14):5990-6017. doi: 10.1021/acs.jmedchem.6b01850. Epub 2017 Apr 20.
3
Identification of Selective Acyl Sulfonamide-Cycloalkylether Inhibitors of the Voltage-Gated Sodium Channel (Na) 1.7 with Potent Analgesic Activity.鉴定电压门控钠离子通道(Na)1.7 的选择性酰基磺酰胺-环烷基醚抑制剂,具有强效的镇痛活性。
J Med Chem. 2019 Jan 24;62(2):908-927. doi: 10.1021/acs.jmedchem.8b01621. Epub 2018 Dec 21.
4
Design of Conformationally Constrained Acyl Sulfonamide Isosteres: Identification of N-([1,2,4]Triazolo[4,3- a]pyridin-3-yl)methane-sulfonamides as Potent and Selective hNa1.7 Inhibitors for the Treatment of Pain.构象限制的酰基磺酰胺等排体的设计:鉴定 N-([1,2,4]三唑并[4,3-a]吡啶-3-基)甲磺酰胺类化合物作为治疗疼痛的强效和选择性 hNa1.7 抑制剂。
J Med Chem. 2018 Jun 14;61(11):4810-4831. doi: 10.1021/acs.jmedchem.7b01826. Epub 2018 May 23.
5
Discovery of Acyl-sulfonamide Na1.7 Inhibitors GDC-0276 and GDC-0310.酰基磺酰胺 Na1.7 抑制剂 GDC-0276 和 GDC-0310 的发现。
J Med Chem. 2021 Mar 25;64(6):2953-2966. doi: 10.1021/acs.jmedchem.1c00049. Epub 2021 Mar 8.
6
Sulfonamides as Selective Na1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities.作为选择性Na1.7抑制剂的磺胺类药物:在减轻代谢负担的同时优化效力和药代动力学。
J Med Chem. 2017 Jul 27;60(14):5969-5989. doi: 10.1021/acs.jmedchem.6b01851. Epub 2017 Apr 20.
7
The discovery of tetrahydropyridine analogs as hNav1.7 selective inhibitors for analgesia.作为用于镇痛的hNav1.7选择性抑制剂的四氢吡啶类似物的发现。
Bioorg Med Chem Lett. 2017 May 15;27(10):2210-2215. doi: 10.1016/j.bmcl.2017.03.043. Epub 2017 Mar 18.
8
The discovery of benzoxazine sulfonamide inhibitors of Na1.7: Tools that bridge efficacy and target engagement.钠通道蛋白1.7的苯并恶嗪磺酰胺抑制剂的发现:连接疗效与靶点结合的工具。
Bioorg Med Chem Lett. 2017 Aug 1;27(15):3477-3485. doi: 10.1016/j.bmcl.2017.05.070. Epub 2017 Jun 1.
9
1,2,4-Triazolsulfone: A novel isosteric replacement of acylsulfonamides in the context of Na1.7 inhibition.1,2,4-三唑砜:在抑制Na1.7的背景下,一种新型的酰基磺酰胺等排体替代物。
Bioorg Med Chem Lett. 2018 Jun 15;28(11):2103-2108. doi: 10.1016/j.bmcl.2018.04.035. Epub 2018 Apr 17.
10
Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of Na1.7.临床候选药物4-[2-(5-氨基-1H-吡唑-4-基)-4-氯苯氧基]-5-氯-2-氟-N-(1,3-噻唑-4-基)苯磺酰胺(PF-05089771)的发现:作为Na1.7选择性抑制剂的二芳基醚芳基磺酰胺的设计与优化
J Med Chem. 2017 Aug 24;60(16):7029-7042. doi: 10.1021/acs.jmedchem.7b00598. Epub 2017 Aug 10.

引用本文的文献

1
Construction of Biaryl Sulfonamides via Pd(II)-Catalyzed Cross-Coupling of C(sp)-H Bonds with Iodobenzenesulfonamides.通过钯(II)催化的C(sp)-H键与碘苯磺酰胺的交叉偶联构建联芳基磺酰胺
ACS Omega. 2025 Apr 21;10(17):17361-17393. doi: 10.1021/acsomega.4c10558. eCollection 2025 May 6.
2
Discordance between preclinical and clinical testing of Na V 1.7-selective inhibitors for pain.用于疼痛治疗的Na V 1.7选择性抑制剂临床前测试与临床试验结果不一致。
Pain. 2025 Mar 1;166(3):481-501. doi: 10.1097/j.pain.0000000000003425. Epub 2024 Oct 23.
3
Cryo-EM reveals an unprecedented binding site for Na1.7 inhibitors enabling rational design of potent hybrid inhibitors.
低温电子显微镜揭示了一个前所未有的钠离子通道 Na1.7 抑制剂结合位点,使强效混合型抑制剂的合理设计成为可能。
Elife. 2023 Mar 28;12:e84151. doi: 10.7554/eLife.84151.
4
Inhibition of Na1.7: the possibility of ideal analgesics.抑制Na1.7:理想镇痛药的可能性。
RSC Med Chem. 2022 Aug 1;13(8):895-920. doi: 10.1039/d2md00081d. eCollection 2022 Aug 17.
5
Discovery of aryl sulfonamide-selective Nav1.7 inhibitors with a highly hydrophobic ethanoanthracene core.发现具有高度疏水性乙氧蒽核心的芳基磺胺类选择性 Nav1.7 抑制剂。
Acta Pharmacol Sin. 2020 Mar;41(3):293-302. doi: 10.1038/s41401-019-0267-z. Epub 2019 Jul 17.
6
Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent Na1.7 inhibitors.哌嗪酰胺作为选择性、状态依赖性Na1.7抑制剂的发现与苗头化合物到先导化合物的评估
Medchemcomm. 2016 Dec 2;8(4):744-754. doi: 10.1039/c6md00578k. eCollection 2017 Apr 1.
7
Mechanism-specific assay design facilitates the discovery of Nav1.7-selective inhibitors.针对特定机制的检测设计有助于发现 Nav1.7 选择性抑制剂。
Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E792-E801. doi: 10.1073/pnas.1713701115. Epub 2018 Jan 8.
8
Sodium channels in pain disorders: pathophysiology and prospects for treatment.疼痛性疾病中的钠通道:病理生理学与治疗前景
Pain. 2017 Apr;158 Suppl 1(Suppl 1):S97-S107. doi: 10.1097/j.pain.0000000000000854.